These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26472525)

  • 1. The Role of Nicotine in Schizophrenia.
    Featherstone RE; Siegel SJ
    Int Rev Neurobiol; 2015; 124():23-78. PubMed ID: 26472525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
    Levin ED; Rezvani AH
    Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinic-antipsychotic drug interactions and cognitive function.
    Levin ED; Rezvani AH
    EXS; 2006; 98():185-205. PubMed ID: 17019889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.
    Potter D; Summerfelt A; Gold J; Buchanan RW
    Schizophr Bull; 2006 Oct; 32(4):692-700. PubMed ID: 16469942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
    Martin LF; Kem WR; Freedman R
    Psychopharmacology (Berl); 2004 Jun; 174(1):54-64. PubMed ID: 15205879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
    Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
    Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
    Boggs DL; Carlson J; Cortes-Briones J; Krystal JH; D'Souza DC
    Curr Pharm Des; 2014; 20(31):5077-92. PubMed ID: 24345265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.
    Radek RJ; Kohlhaas KL; Rueter LE; Mohler EG
    Curr Pharm Des; 2010 Jan; 16(3):309-22. PubMed ID: 20109141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.
    Wallace TL; Bertrand D
    Expert Opin Ther Targets; 2013 Feb; 17(2):139-55. PubMed ID: 23231385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
    Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
    J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia.
    Rowe AR; Mercer L; Casetti V; Sendt KV; Giaroli G; Shergill SS; Tracy DK
    J Psychopharmacol; 2015 Feb; 29(2):197-211. PubMed ID: 25567553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
    Freedman R
    Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia and nicotinic receptors.
    Freedman R; Adler LE; Bickford P; Byerley W; Coon H; Cullum CM; Griffith JM; Harris JG; Leonard S; Miller C
    Harv Rev Psychiatry; 1994; 2(4):179-92. PubMed ID: 9384901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
    Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
    Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
    Siegel SJ; Maxwell CR; Majumdar S; Trief DF; Lerman C; Gur RE; Kanes SJ; Liang Y
    Neuroscience; 2005; 133(3):729-38. PubMed ID: 15908134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia.
    Griffith JM; O'Neill JE; Petty F; Garver D; Young D; Freedman R
    Biol Psychiatry; 1998 Jul; 44(2):98-106. PubMed ID: 9646891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropisetron improves deficits in auditory P50 suppression in schizophrenia.
    Koike K; Hashimoto K; Takai N; Shimizu E; Komatsu N; Watanabe H; Nakazato M; Okamura N; Stevens KE; Freedman R; Iyo M
    Schizophr Res; 2005 Jul; 76(1):67-72. PubMed ID: 15927799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.